secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vitro Biopharma, Inc. (—)
CIK:        0000793171
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0001493152-22-035733
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vitro Biopharma to restate Q3/Q1 FY2022 financials due to revenue recognition error; net loss increases $22.9k
--------------------------------------------------------------------------------

- Restating unaudited interim statements for three and nine months ended July 31, 2022 under ASC 606.
- Revenue to decrease by $200,000; G&A expenses to decrease by $177,147; net loss to increase by $22,853.
- Error stems from contract with European Wellness Biomedical Group and its subsidiary BioPep.
- Material weakness identified in internal control over revenue recognition as of July 31, 2022.
- Company expects to file amended Form 10-12G with restated financial statements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/793171/000149315222035733/0001493152-22-035733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/793171/000149315222035733/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-035733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer